Survivin, a Molecular Target for Therapeutic Interventions in Squamous Cell Carcinoma

Overview

Journal Cell Mol Biol Lett

Publisher Biomed Central

Specialties Biochemistry
Cell Biology
Molecular Biology

Date 2017 May 25

PMID 28536639

Citations 43

Authors

Zakir Khan

Abdul Arif Khan

Hariom Yadav

Godavarthi B K S Prasad

Prakash Singh Bisen

Affiliations

Soon will be listed here.

Abstract

Squamous cell carcinoma (SCC) is the most common cancer worldwide. The treatment of locally advanced disease generally requires various combinations of radiotherapy, surgery, and systemic therapy. Despite aggressive multimodal treatment, most of the patients relapse. Identification of molecules that sustain cancer cell growth and survival has made molecular targeting a feasible therapeutic strategy. Survivin is a member of the Inhibitor of Apoptosis Protein (IAP) family, which is overexpressed in most of the malignancies including SCC and totally absent in most of the normal tissues. This feature makes survivin an ideal target for cancer therapy. It orchestrates several important mechanisms to support cancer cell survival including inhibition of apoptosis and regulation of cell division. Overexpression of survivin in tumors is also associated with poor prognosis, aggressive tumor behavior, resistance to therapy, and high tumor recurrence. Various strategies have been developed to target survivin expression in cancer cells, and their effects on apoptosis induction and tumor growth attenuation have been demonstrated. In this review, we discuss recent advances in therapeutic potential of survivin in cancer treatment.

Citing Articles

Lotus seed extract: anticancer potential and chemoprofiling by , and GC-MS studies.

Mallela V, Rudrapal M, Prasanth D, Pasala P, Bendale A, Bhattacharya S Front Chem. 2024; 12:1505272.

PMID: 39734578 PMC: 11671802. DOI: 10.3389/fchem.2024.1505272.

Prognostic and clinicopathological significance of survivin in gynecological cancer.

Chuwa A, Mvunta D Oncol Rev. 2024; 18:1444008.

PMID: 39687493 PMC: 11646728. DOI: 10.3389/or.2024.1444008.

Effects of Resveratrol on Nonmelanoma Skin Cancer (NMSC): A Comprehensive Review.

Zamanian M, Shahbazi T, Kazmi S, Hussien B, Sharma A, Qasim M Food Sci Nutr. 2024; 12(11):8825-8845.

PMID: 39620024 PMC: 11606877. DOI: 10.1002/fsn3.4555.

P4HA2 promotes proliferation, invasion, and metastasis through regulation of the PI3K/AKT signaling pathway in oral squamous cell carcinoma.

Chi Z, Wang Q, Wang X, Li D, Tong L, Shi Y Sci Rep. 2024; 14(1):15023.

PMID: 38951593 PMC: 11217378. DOI: 10.1038/s41598-024-64264-5.

Natural Prenylflavones from the Stem Bark of : Promising Anticancer Agents for Oral Squamous Cell Carcinoma Targeting the Akt/mTOR/STAT-3 Signaling Pathway.

Aswathy M, Parama D, Hegde M, Dr S, Lankalapalli R, Radhakrishnan K ACS Omega. 2024; 9(23):24252-24267.

PMID: 38882137 PMC: 11170706. DOI: 10.1021/acsomega.3c08376.

References

Pennati M, Campbell A, Curto M, Binda M, Cheng Y, Wang L . Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. Mol Cancer Ther. 2005; 4(9):1328-37. DOI: 10.1158/1535-7163.MCT-05-0022. View

Tu S, Jiang X, Lin M, Cui J, Yang Y, Lum C . Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res. 2003; 63(22):7724-32. View

Khan K, Blanco-Codesido M, Molife L . Cancer therapeutics: Targeting the apoptotic pathway. Crit Rev Oncol Hematol. 2014; 90(3):200-19. DOI: 10.1016/j.critrevonc.2013.12.012. View

Grabowski P, Griss S, Arnold C, Horsch D, Goke R, Arnold R . Nuclear survivin is a powerful novel prognostic marker in gastroenteropancreatic neuroendocrine tumor disease. Neuroendocrinology. 2005; 81(1):1-9. DOI: 10.1159/000084892. View

Hu J, Pan J, Luo Z, Tao Z . Downregulation of Survivin by shRNA Inhibits Invasion and Enhances the Radiosensitivity of Laryngeal Squamous Cell Carcinoma. Cell Biochem Biophys. 2015; 72(1):251-7. DOI: 10.1007/s12013-014-0445-z. View

Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M . YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res. 2007; 67(17):8014-21. DOI: 10.1158/0008-5472.CAN-07-1343. View

Dallaglio K, Petrachi T, Marconi A, Truzzi F, Lotti R, Saltari A . Expression of nuclear survivin in normal skin and squamous cell carcinoma: a possible role in tumour invasion. Br J Cancer. 2013; 110(1):199-207. PMC: 3887296. DOI: 10.1038/bjc.2013.697. View

Chang C, Heller J, Kuo J, Huang R . Tetra-O-methyl nordihydroguaiaretic acid induces growth arrest and cellular apoptosis by inhibiting Cdc2 and survivin expression. Proc Natl Acad Sci U S A. 2004; 101(36):13239-44. PMC: 516554. DOI: 10.1073/pnas.0405407101. View

Wu C, Chang Y, Chang K, Liu Y, Liu H, Lee I . Salivary auto-antibodies as noninvasive diagnostic markers of oral cavity squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2014; 23(8):1569-78. DOI: 10.1158/1055-9965.EPI-13-1269. View

10.

Plescia J, Salz W, Xia F, Pennati M, Zaffaroni N, Daidone M . Rational design of shepherdin, a novel anticancer agent. Cancer Cell. 2005; 7(5):457-68. DOI: 10.1016/j.ccr.2005.03.035. View

11.

OConnor D, Grossman D, Plescia J, Li F, Zhang H, Villa A . Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci U S A. 2000; 97(24):13103-7. PMC: 27185. DOI: 10.1073/pnas.240390697. View

12.

Abu-El-Asrar A, Dralands L, Missotten L, Al-Jadaan I, Geboes K . Expression of apoptosis markers in the retinas of human subjects with diabetes. Invest Ophthalmol Vis Sci. 2004; 45(8):2760-6. DOI: 10.1167/iovs.03-1392. View

13.

OConnor D, Wall N, Porter A, Altieri D . A p34(cdc2) survival checkpoint in cancer. Cancer Cell. 2002; 2(1):43-54. DOI: 10.1016/s1535-6108(02)00084-3. View

14.

Jiang G, Li J, Zeng Z, Xian L . Lentivirus-mediated gene therapy by suppressing survivin in BALB/c nude mice bearing oral squamous cell carcinoma. Cancer Biol Ther. 2006; 5(4):435-40. DOI: 10.4161/cbt.5.4.2542. View

15.

Gold D, Shroeder K, Golding A, Brostoff S, Wilson D . T-cell receptor peptides as immunotherapy for autoimmune disease. Crit Rev Immunol. 1997; 17(5-6):507-10. View

16.

Lotti R, Palazzo E, Petrachi T, Dallaglio K, Saltari A, Truzzi F . Survivin Modulates Squamous Cell Carcinoma-Derived Stem-Like Cell Proliferation, Viability and Tumor Formation in Vivo. Int J Mol Sci. 2016; 17(1). PMC: 4730332. DOI: 10.3390/ijms17010089. View

17.

Wochner A, Attwater J, Coulson A, Holliger P . Ribozyme-catalyzed transcription of an active ribozyme. Science. 2011; 332(6026):209-12. DOI: 10.1126/science.1200752. View

18.

Wang Z, Sampath J, Fukuda S, Pelus L . Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis. Cancer Res. 2005; 65(18):8224-32. DOI: 10.1158/0008-5472.CAN-05-0303. View

19.

Guo F, Sigua C, Tao J, Bali P, George P, Li Y . Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res. 2004; 64(7):2580-9. DOI: 10.1158/0008-5472.can-03-2629. View

20.

Olie R, Simoes-Wust A, Baumann B, Leech S, Fabbro D, Stahel R . A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res. 2000; 60(11):2805-9. View